Showing results (31-40 of 37) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 37 results.
Journal of Hematology & Oncology|August 16, 2024
Comparisons of treatment outcomes of epcoritamab versus chemoimmunotherapy, polatuzumab-based regimens, tafasitamab-based regimens, or chimeric antigen receptor T-cell therapy, in third-line or later relapsed/refractory large B-cell lymphomaAllison Rosenthal, Javier Munoz, Monika Jun, et al.
JCO Precision Oncology|February 1, 2022
Economic Impact of Next-Generation Sequencing Versus Single-Gene Testing to Detect Genomic Alterations in Metastatic Non-Small-Cell Lung Cancer Using a Decision Analytic ModelNathan A Pennell, Alex Mutebi, Zheng-Yi Zhou, et al.
Future Oncology (London, England)|August 13, 2025
Clinical representativeness of pivotal trials for T-cell engagers in relapsed/refractory follicular lymphomaZhijie Ding, Guihua Zhang, Junhua Yu, et al.
Lung Cancer (Amsterdam, Netherlands)|January 16, 2019
Real-world treatment patterns and survival of patients with BRAF V600-mutated metastatic non-small cell lung cancerLeora Horn, Joshua Bauml, Patrick M Forde, et al.
Blood Advances|June 5, 2025
Indirect comparison of epcoritamab vs chemoimmunotherapy, mosunetuzumab, or odronextamab in follicular lymphomaAlexey V Danilov, Swetha Kambhampati Thiruvengadam, Kim Linton, et al.
Clinical Lymphoma, Myeloma & Leukemia|November 8, 2025
Epcoritamab Plus Gemcitabine and Oxaliplatin Versus Rituximab Plus Gemcitabine and Oxaliplatin in Transplant-Ineligible Relapsed/Refractory Diffuse Large B-Cell Lymphoma: A Match-Adjusted Comparative AnalysisJavier Munoz, Allison Rosenthal, Andrew Ip, et al.
Clinical Lymphoma, Myeloma & Leukemia|February 18, 2025
Real-World Effectiveness of Chemoimmunotherapy and Novel Therapies for Patients With Relapsed/Refractory Aggressive Large B-Cell LymphomaLoretta J Nastoupil, Clark R Andersen, Amy Ayers, et al.
Pageof 4